BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hypochondroplasia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Hypochondroplasia\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07126262-10775@assetmemo.bio
DTSTAMP:20261121T005404Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:VOXZOGO (Vosoritide): Phase 2 readout est. (NCT07126262)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 2\, Hypochondroplasia.\nStudy: A S
 tudy of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 
 0 to < 36 Months\nEstimated primary completion: 30 June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07126262
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073014-10775@assetmemo.bio
DTSTAMP:20261121T005404Z
DTSTART;VALUE=DATE:20441031
DTEND;VALUE=DATE:20441101
SUMMARY:VOXZOGO (Vosoritide): Phase 3 readout est. (NCT07073014)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 3\, Hypochondroplasia.\nStudy: Lon
 g-Term Extension Study of Vosoritide to Treat Children With Hypochondropla
 sia\nEstimated primary completion: October 2044. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07073014
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
